Form 4: Avalo Therapeutics Director Aaron Kantoff Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Director Aaron Kantoff received stock options and restricted stock units from Avalo Therapeutics on August 13, 2024.
Summary
- On August 13, 2024, Aaron Kantoff, a director of Avalo Therapeutics, Inc., was granted stock options to purchase 24,600 shares of common stock at an exercise price of $9.88 per share.
- These options vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent upon Kantoff's continued service.
- Kantoff also received 9,500 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting.
- The RSUs also vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, subject to continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, indicating a stable and incentivized management structure. This is generally viewed positively.
Positives
- The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
- The vesting schedule encourages continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This is a standard practice for incentivizing and retaining key personnel in publicly traded companies, particularly directors.
Comparison to Industry Standards
- Granting stock options and RSUs to directors is a common practice in the biotechnology industry to align their interests with shareholders.
- The vesting schedule of one-third per year over three years is also a typical arrangement.
- Comparable companies like BioNTech or Moderna also use equity-based compensation for their directors.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning director interests with company performance.
- Employees may see this as a sign of stability and commitment to leadership.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date of transaction: Grant of stock options and restricted stock units. |
| 08/14/2024 | Date of Form 4 signature. |
| 03/28/2025 | First vesting date for 1/3 of stock options and RSUs. |
| 03/28/2026 | Second vesting date for 1/3 of stock options and RSUs. |
| 03/28/2027 | Final vesting date for 1/3 of stock options and RSUs. |
| 08/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.